PE20001108A1 - Concentrado oral de sertralina - Google Patents
Concentrado oral de sertralinaInfo
- Publication number
- PE20001108A1 PE20001108A1 PE1999001025A PE00102599A PE20001108A1 PE 20001108 A1 PE20001108 A1 PE 20001108A1 PE 1999001025 A PE1999001025 A PE 1999001025A PE 00102599 A PE00102599 A PE 00102599A PE 20001108 A1 PE20001108 A1 PE 20001108A1
- Authority
- PE
- Peru
- Prior art keywords
- sodium
- sertraline
- aqueous
- metabisulphye
- achyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE UN CONCENTRADO LIQUIDO ESENCIALMENTE NO ACUOSO PARA LA ADMINISTRACION ORAL QUE COMPRENDE a)DE 15 mg/ml A 30 mg/ml DE SERTRALINA O SAL CLORHIDRATO O SAL MESILATO; b)EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES NO ACUOSOS, DONDE AL MENOS UNO ES LIQUIDO; TAL COMO ETANOL, GLICERINA, POLIETILENGLICOL, PROPILENGLICOL; DE PREFERENCIA DE 8% A 20% DE ETANOL (EN PESO) EN GLICERINA; c)AGENTES AROMATIZANTES (MENTA, MENTA VERDE, MENTOL) O CONSERVANTES (BUTILHIDROXITOLUENO, HIDROXIANISOLBUTILADO, GALATO DE PROPILO, ACIDO ASCORBICO, PALMITATO DE ASCORBILO, METABISULFITO SODICO, BISULFITO SODICO, ENTRE OTROS. TAMBIEN SE REFIERE A LA PREPARACION DE UNA SOLUCION ACUOSA DE SERTRALINA QUE COMPRENDE DILUIR EL CONCENTRADO LIQUIDO EN UN DILUYENTE ACUOSO TAL COMO AGUA, ZUMO DE NARANJA, GASEOSA DE JENGIBRE, GASEOSA DE LIMON-LIMA Y LIMONADA. TAMBIEN SE REFIERE AL COMPUESTO (1S-CIS)-4-(3,4-DICLOROFENIL)-1,2,3,4-TETRAHIDRO-N-METIL-1-NAFTALENOAMINA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10402498P | 1998-10-13 | 1998-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001108A1 true PE20001108A1 (es) | 2000-10-26 |
Family
ID=22298286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001025A PE20001108A1 (es) | 1998-10-13 | 1999-10-11 | Concentrado oral de sertralina |
Country Status (45)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02001811A (es) | 1999-09-03 | 2002-08-06 | Lilly Co Eli | Metodos de uso de inhibidores de la reabsorcion de la serotonina selectivos, de inicio rapido de accion para el tratamiento de la disfuncion sexual. |
| US20030086972A1 (en) * | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
| WO2004065348A1 (en) | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| JP2007502329A (ja) * | 2003-05-23 | 2007-02-08 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | セルトラリン組成物 |
| WO2005034910A1 (en) * | 2003-10-08 | 2005-04-21 | Ranbaxy Laboratories Limited | Oral liquid pharmaceutical compositions of sertraline |
| WO2007052152A2 (en) * | 2005-11-07 | 2007-05-10 | Aurobindo Pharma Limited | Sertraline oral concentrate |
| EP2131827A2 (en) | 2007-03-09 | 2009-12-16 | New York University | Methods and compositions for treating thalamocortical dysrhythmia |
| CN109908354A (zh) * | 2017-12-12 | 2019-06-21 | 万特制药(海南)有限公司 | 盐酸舍曲林口服浓缩液及其制备工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US5130338A (en) * | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
| US4940731A (en) * | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
| ATE96999T1 (de) * | 1989-08-30 | 1993-11-15 | Pfizer | Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen. |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| SE508372C2 (sv) * | 1995-02-13 | 1998-09-28 | Kjell Lindstroem | Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar |
| EP0768083B1 (en) * | 1995-07-17 | 2003-03-26 | Pfizer Inc. | Sertraline for treating post myocardial infarction patients |
| PL337807A1 (en) * | 1997-07-01 | 2000-09-11 | Pfizer Prod Inc | Sertralin dosage formulation in the form of a gelatine-encapsulated solution |
-
1999
- 1999-09-22 CA CA002346335A patent/CA2346335C/en not_active Expired - Fee Related
- 1999-09-22 PL PL99348119A patent/PL348119A1/xx not_active Application Discontinuation
- 1999-09-22 EE EEP200100221A patent/EE04868B1/xx not_active IP Right Cessation
- 1999-09-22 EA EA200100285A patent/EA003990B1/ru not_active IP Right Cessation
- 1999-09-22 HR HR20010263A patent/HRP20010263B1/xx not_active IP Right Cessation
- 1999-09-22 WO PCT/IB1999/001571 patent/WO2000021521A2/en not_active Ceased
- 1999-09-22 SK SK458-2001A patent/SK4582001A3/sk unknown
- 1999-09-22 CZ CZ20011286A patent/CZ20011286A3/cs unknown
- 1999-09-22 AT AT99943168T patent/ATE254453T1/de not_active IP Right Cessation
- 1999-09-22 UA UA2001042450A patent/UA72743C2/uk unknown
- 1999-09-22 BR BR9914418-2A patent/BR9914418A/pt not_active Application Discontinuation
- 1999-09-22 TR TR2001/01090T patent/TR200101090T2/xx unknown
- 1999-09-22 DE DE69912978T patent/DE69912978T2/de not_active Expired - Fee Related
- 1999-09-22 OA OA1200100087A patent/OA11662A/en unknown
- 1999-09-22 PT PT99943168T patent/PT1121107E/pt unknown
- 1999-09-22 YU YU26401A patent/YU26401A/sh unknown
- 1999-09-22 HU HU0104470A patent/HUP0104470A3/hu unknown
- 1999-09-22 NZ NZ510756A patent/NZ510756A/en unknown
- 1999-09-22 JP JP2000575497A patent/JP3792514B2/ja not_active Expired - Fee Related
- 1999-09-22 ID IDW20010824A patent/ID29845A/id unknown
- 1999-09-22 AU AU56436/99A patent/AU766202B2/en not_active Ceased
- 1999-09-22 CN CNB998120871A patent/CN1184962C/zh not_active Expired - Fee Related
- 1999-09-22 AP APAP/P/2001/002119A patent/AP2001002119A0/en unknown
- 1999-09-22 HK HK02101974.6A patent/HK1040199B/zh not_active IP Right Cessation
- 1999-09-22 EP EP99943168A patent/EP1121107B1/en not_active Expired - Lifetime
- 1999-09-22 KR KR10-2001-7004559A patent/KR100417200B1/ko not_active Expired - Fee Related
- 1999-09-22 ES ES99943168T patent/ES2209490T3/es not_active Expired - Lifetime
- 1999-09-22 GE GEAP19995852A patent/GEP20032969B/en unknown
- 1999-09-22 DK DK99943168T patent/DK1121107T3/da active
- 1999-09-28 PA PA19998483301A patent/PA8483301A1/es unknown
- 1999-10-05 GT GT199900171A patent/GT199900171A/es unknown
- 1999-10-06 TW TW088117244A patent/TWI228043B/zh not_active IP Right Cessation
- 1999-10-08 AR ARP990105116A patent/AR014082A1/es unknown
- 1999-10-09 GC GCP1999314 patent/GC0000175A/en active
- 1999-10-11 MY MYPI99004384A patent/MY122477A/en unknown
- 1999-10-11 PE PE1999001025A patent/PE20001108A1/es not_active Application Discontinuation
- 1999-10-12 DZ DZ990213A patent/DZ2913A1/xx active
- 1999-10-12 TN TNTNSN99190A patent/TNSN99190A1/fr unknown
- 1999-10-12 EG EG127599A patent/EG23818A/xx active
- 1999-10-12 MA MA25814A patent/MA26698A1/fr unknown
- 1999-10-13 CO CO99065089A patent/CO5150213A1/es unknown
-
2001
- 2001-03-23 IS IS5906A patent/IS2239B/is unknown
- 2001-04-09 ZA ZA200102900A patent/ZA200102900B/xx unknown
- 2001-04-10 BG BG105434A patent/BG65085B1/bg unknown
- 2001-04-10 NO NO20011829A patent/NO20011829L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073793A1 (es) | Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido | |
| CR6458A (es) | Composiciones de valdecoxib | |
| WO2003105800A3 (de) | Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen | |
| RU2006118801A (ru) | Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина | |
| JPH11511758A (ja) | 鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬 | |
| DK1526839T3 (da) | Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed | |
| UY25374A1 (es) | Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina | |
| MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
| NZ581589A (en) | Solubilized sterile injectable formulation of docetaxel without Tween 80 | |
| JP2001187728A (ja) | 眼科用組成物 | |
| PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| PE20001108A1 (es) | Concentrado oral de sertralina | |
| AR034370A1 (es) | Una preparacion farmaceutica acuosa de cilostazol para uso parenteral | |
| AR036312A1 (es) | Composicion farmaceutica | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| JP2009161454A (ja) | 眼科用組成物 | |
| JP2005015368A (ja) | プラノプロフェン含有水性液剤の安定化方法 | |
| AR041069A1 (es) | Composicion de tolterodina liquida oral | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| ES2174388T3 (es) | Solucion liquida de medicamento para administracion oral. | |
| UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
| ES2197781B1 (es) | Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno. | |
| JP5052028B2 (ja) | アシタザノラスト含有組成物 | |
| ECSP066274A (es) | Saquinavir mesilato, forma de dosificacion oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |